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Introduction
Systemic AL amyloidosis is a protein deposition disease in which the underlying clonal proliferation of plasma cells produce excess of unstable immunoglobulin light chains, with deposition of immunoglobulin light chains in tissues and organs leading to impairment of the latter. 1, 2 Tracking and monitoring AL amyloidosis is a challenge as most patients have barely a detectable intact monoclonal immunoglobulin. The discovery of serum free light chains as a measure in 2000, led to a development that revolutionised this rare disease.
The serum Freelite TM assay measures immunoglobulin free light chains using polyclonal sheep antibodies directed against hidden epitopes on the light chain molecule giving an accurate measurement of serum free kappa and lambda. Our group initially reported the utility of this assay in 2002 3 in this disease, with many studies following. This assay now forms a standard part of the baseline and serial follow up assessments in systemic AL amyloidosis 4, 5 , and is part of the revised Mayo staging system and standard international consensus criteria for disease response assessment. [6] [7] [8] Polyclonal antibodies to light chain epitopes in the Freelite TM assay continue to be prepared from specifically immunised sheep. However, in any naturally occurring antibody mixture, standardisation remains complex and inter-assay variability is a distinct possibility. Efforts have been made to develop monoclonal antibodies to the hidden light chain epitopes that would recognise and replicate the success of the polyclonal assay and allow better inter-assay standardisation. A group in the Netherlands working with Siemens, Germany, has developed this technology using a mixture to two kappa and two lambda monoclonal antibodies to the hidden epitopes of the constant region of the immunoglobulin light chain molecules. 9 The references ranges of both the new N-Latex assay and the polyclonal Freelite TM assay are similar.
With increasing adoption by laboratories of the novel assay, it is important to assess the utility of the new assay compared to the current reference Freelite TM assay. We report a comparison of serum free light chains measured both immunoassays at diagnosis and three further time points in during the initial chemotherapy for patients with systemic AL amyloidosis.
Materials and Methods
This study was conducted at the National Amyloidosis Centre, London, UK (NAC).
Consecutive patients with systemic AL amyloidosis seen at the NAC and under prospective follow up from January 2011 and April 2012 undergoing chemotherapy for AL amyloidosis were included, if they had a baseline serum sample at initial diagnosis and at least 3 of 4 blood samples available including from baseline 2, 4 and 6 month follow up point intervals following treatment with chemotherapy. We performed a correlation analysis between the 2 FLC assays of results for kappa, lambda and kappa/lambda ratio, examining the qualitative comparison.
Haematologic response was assessed as per the international amyloidosis consensus criteria, 6,7 typically developed using results obtained from the Freelite TM assay. This study was not powered to develop new response criteria for the N-latex assay. Statistical analysis was performed using SPSS software with a p value of less than 0.05 considered to be significant. We have stated median values with minimum and maximum ranges. We calculated the Pearson's coefficient to evaluate the agreement and concordance between the two FLC assays, with use of scatter plots to illustrate this. Kaplan Meier curves were used to assess prognostic utility of both assays.
Results
A total of 94 patients were identified from the National Amyloidosis database over Table 1 ).
There were discordant kappa/lambda ratios at presentation with 10/90 abnormal by Freelite TM but normal by N Latex assay, and 11/90 abnormal by N Latex and normal by Freelite TM (Table 2 ). There were 10 patients with an abnormal ĸ/Ɩ ratio by The diagnostic sensitivity (true positive) and specificity (true negative) with agreement of the ĸ/Ɩ ratios of the FreeliteTM and N Latex assays were calculated (Table 3 and Table 4 ).
We evaluated the clinical impact of these differences in assessing haematologic response according to the revised Consensus criteria 7 of those with measurable dFLC at 2, 4 and 6 months post chemotherapy treatment for patients with sampels available at each of these time points. At baseline 54 (60%) and 51 (56.7%) had a dFLC >50 mg/L (the minimum defined to assess the free light chain response). Using 
Discussion
We report here the comparative utility of using two different assays (one using polyclonal anti-light chain antibodies and other using a combination of monoclonal anti-light chain antibodies) for detection of and serial monitoring of serum free light chains in patients with systemic AL amyloidosis undergoing chemotherapy. This study finds that the two assays are broadly comparable for detection of abnormal light chains in the serum with a greater concordance for detection of kappa than for lambda immunoglobulin free light chain. However, discrepancies were also present with the numbers abnormal, the absolute light chain value and time point to reach thresholds for haematological responses different in some which may also impact on survival.
The Freelite TM assay was the only assay available for measurement of serum free light chains until the development of the N-Latex assay, allowing a different method to study these complex molecules; but standardisation is needed between the two assays. Both assays have been studied in myeloma as well as normal controls to assess imprecision, underestimation; antigen excess or non-linear reactivity and overestimation; polymeric forms reacting at multiple antigenic FLC sites of results. [11] [12] [13] However, it is important to emphasise that the free light chain component in Myeloma is higher than in patients with AL amyloidosis, and as such direct extrapolation of the results from our study cannot be translated with regard to Myeloma patients. Our study was not focused on the biochemical or technical aspects of either assay, but was designed to assess the clinical utility of each assay in a routine clinical setting in systemic where the serum free light chains are typically abnormal, but low and where FLC measurements form the cornerstone of patient assessment and monitoring. In previous studies in patients with a monoclonal gammopathy, the kappa showed the best correlation between both FLC assays, The current study confirms that in systemic AL amyloidosis, there is, in general, excellent concordance between both the assays in detecting an excess of serum free light chains with better concordance of kappa than lambda as previously reported. The overall concordance in our study for kappa, lambda and kappa/lambda ratios were 85.5%, 75.5% and 78.8% respectively -similar to another study 70-80%
14 but lower than another study quoting the concordance as approximately 90%. 9 The diagnostic sensitivity with respect to the serum and urine IFE results was lower 
